CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...

Seq, a CRISPR-based method that enriches ultra-rare tumor DNA in blood by removing background wild-type DNA before sequencing ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...

The answer is yes, absolutely, absolutely 100%. but it's not all kinds of math, and it's not all kinds of programming. that ...

Every face is unique. Genetics helps to determine our features, but sometimes genes have errors, which, in early fetal development, can result in ...

Chinese scientists have genetically tweaked a fungus to make protein-rich “meat”, which they say can be a low-cost, ...

On November 18, 2025, ToolGen, Inc. (“ToolGen”) filed a complaint (“Complaint”) in the District of Massachusetts alleging infringement of its ...